| Family: | Virtus ETF Solutions |
| Name: | Virtus LifeSci Biotech Products ETF |
| Inception Date: | 17-Dec-2014 |
| Termination Date: | |
| Investment Objective: | Virtus LifeSci Biotech Products ETF (the "Products Fund") is an exchange-traded fund incorporated in the USA. The Fund seeks investment results that correspond to the performance of the LifeSci Biotechnology Products Index. Products stage companies are typically more established companies with much clinical trial failure risk behind them. |
| Prospectus | |
| Top 10 Holdings | ||
| Dynavax Technologies Corp | DVAX | 2.2209% |
| Amicus Therapeutics Inc | FOLD | 2.1040% |
| Moderna Inc | MRNA | 1.8815% |
| Mirum Pharmaceuticals Inc | MIRM | 1.8284% |
| Halozyme Therapeutics Inc | HALO | 1.8271% |
| Axsome Therapeutics Inc | AXSM | 1.8027% |
| Iovance Biotherapeutics Inc | IOVA | 1.8018% |
| Novavax Inc | NVAX | 1.7603% |
| BioMarin Pharmaceutical Inc | BMRN | 1.7514% |
| Phathom Pharmaceuticals Inc | PHAT | 1.7477% |
| Top 10 Holdings Weight: | 18.7% |
| Number of Holdings: | 66 |
| Shares Outstanding: | 550,004 |
| Total Net Assets: | 45,196,470 |
| NAV: | 82.39 |
| Net Expense Ratio: | 0.79% |
| Asset Class: | Equities (Stocks) |
| Developed or Emerging: | Developed Market Funds |
| Country: | US |
| Region: | |
| Strategy: | |
| Currency: | |
| Commodity: | |
| Sector: | Healthcare |
| Industry: | Biotech |
| Dividend Type: | |
| Tax Exempt State: | |
| Maturity Duration: | |
| Market Cap: | Broad Market / Multi-Cap |
| Credit Quality: | |
| Mortgage Bond Types: | |
| Bond Type: | |
| Gov't Bond Types: | |
| Reit Type: | |
| Leverage Direction/Factor: | |
| Is Currency Hedged: | No |
| US or Ex-US: | Domestic |
